The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Predictors of 30-Day Mortality among Patients with Pseudomonas aeruginosa Bloodstream Infections: Impact of Delayed Appropriate Antibiotic Selection
Open accessAbstract
Although a growing number of studies have found a relationship between delayed appropriate antibiotic therapy and mortality, few have attempted to quantify the temporal association between delayed appropriate antibiotic therapy and mortality. This study was designed to measure the elapsed time associated with an increased risk of 30-day mortality among patients with Pseudomonas aeruginosa bacteremia. The retrospective cohort study was conducted among immunocompetent, adult patients with P. aeruginosa bacteremia onset at least 2 days after hospital admission between 1 January 2001 and 30 September 2006. Classification and regression tree analysis (CART) was used to identify the delay in appropriate antibiotic therapy that was associated with an increased risk of 30-day mortality. During the study period, 100 patients met the inclusion criteria. The CART-derived breakpoint between early and delayed treatment was 52 h. The delayed treatment group experienced a >2-fold significant increase in 30-day mortality compared to the early treatment group (44 and 19%, respectively, P = 0.008). Delayed appropriate therapy of >52 h (odds ratio [OR] = 4.1; 95% confidence interval [CI] 1.2 to 13.9, P = 0.03) was independently associated with 30-day mortality in the multivariate analysis. Antibiotic resistance ≥3 classes (adjusted OR [AOR] = 4.6; 95% CI = 1.9 to 11.2, P = 0.001) and chronic obstructive pulmonary disease (AOR = 5.4; 95% CI = 1.5 to 19.7, P = 0.01) were independently associated with delayed appropriate therapy of >52 h. The data strongly suggest that delaying appropriate therapy for approximately 2 days significantly increases the risk of 30-day mortality in patients with P. aeruginosa bloodstream infections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
APACHE II: A severity of disease classification system
KNAUS, W. A., DRAPER, E. A., WAGNER, D. P., & ZIMMERMAN, J. E. (1985) · Critical Care Medicine · doi:10.1097/00003246-198510000-00009 · Cited by 13,664
APACHE II-A Severity of Disease Classification System: Reply
Knaus, W. A., Draper, E. A., Wagner, D. P., & Zimmerman, J. E. (1986) · Critical Care Medicine · doi:10.1097/00003246-198608000-00028 · Cited by 13,376
APACHE II: a severity of disease classification system.
Knaus, W. A., Draper, E. S., Wagner, D. P., & Zimmerman, J. E. (1985) · PubMed · Cited by 6,034
CDC definitions for nosocomial infections, 1988
Garner, J. S., Jarvis, W. R., Emori, T. G., Horan, T. C., & Hughes, J. M. (1988) · American Journal of Infection Control · doi:10.1016/0196-6553(88)90053-3 · Cited by 5,672
CDC definitions for nosocomial infections
Yangco, B. G. (1989) · American Journal of Infection Control · doi:10.1016/s0196-6553(89)80013-6 · Cited by 3,770
Inadequate Antimicrobial Treatment of Infections
Kollef, M. H., Sherman, G., Ward, S., & Fraser, V. J. (1999) · Chest · doi:10.1378/chest.115.2.462 · Cited by 1,805
Ibrahim, E. H., Sherman, G., Ward, S., Fraser, V. J., & Kollef, M. H. (2000) · Chest · doi:10.1378/chest.118.1.146 · Cited by 1,779
The use of receiver operating characteristic curves in biomedical informatics
Lasko, T. A., Bhagwat, J. G., Zou, K. H., & Ohno-Machado, L. (2005) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2005.02.008 · Cited by 823
Kang, C.-I., Kim, S.-H., Park, W. B., Lee, K.-D., Kim, H.-B., Kim, E.-C., Oh, M.-D., & Choe, K.-W. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.2.760-766.2005 · Cited by 692
The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection
Leibovici, Shraga, Drucker, Konigsberger, Samra, Pitlik, & Pitlik (1998) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.1998.00379.x · Cited by 685
Cited by
Freifeld, A. G., Bow, E. J., Sepkowitz, K. A., Boeckh, M. J., Ito, J. I., Mullen, C. A., Raad, I. I., Rolston, K. V., Young, J.-A. H., & Wingard, J. R. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir073 · Cited by 3,463
Solomkin, J. S., Mazuski, J. E., Bradley, J. S., Rodvold, K. A., Goldstein, E. J. C., Baron, E. J., O'Neill, P. J., Chow, A. W., Dellinger, E. P., Eachempati, S. R., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/649554 · Cited by 1,558
Horcajada, J. P., Montero, M., Oliver, A., Sorlí, L., Luque, S., Gómez-Zorrilla, S., Benito, N., & Grau, S. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00031-19 · Cited by 961
The Multiple Signaling Systems Regulating Virulence in Pseudomonas aeruginosa
Nadal Jimenez, P., Koch, G., Thompson, J. A., Xavier, K. B., Cool, R. H., & Quax, W. J. (2012) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.05007-11 · Cited by 736
Freifeld, A. G., Bow, E. J., Sepkowitz, K. A., Boeckh, M. J., Ito, J. I., Mullen, C. A., Raad, I. I., Rolston, K. V., Young, J.-A. H., & Wingard, J. R. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq147 · Cited by 704
Solomkin, J. S., Mazuski, J. E., Bradley, J. S., Rodvold, K. A., Goldstein, E. J. C., Baron, E. J., O'Neill, P. J., Chow, A. W., Dellinger, E. P., Eachempati, S. R., et al. (2010) · Surgical Infections · doi:10.1089/sur.2009.9930 · Cited by 623
Pseudomonas aeruginosa: a formidable and ever-present adversary
Kerr, K. G., & Snelling, A. M. (2009) · Journal of Hospital Infection · doi:10.1016/j.jhin.2009.04.020 · Cited by 549
Impact of multidrug-resistant Pseudomonas aeruginosa infection on patient outcomes
Hirsch, E. B., & Tam, V. H. (2010) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/erp.10.49 · Cited by 406
Perez, K. K., Olsen, R. J., Musick, W. L., Cernoch, P. L., Davis, J. R., Land, G. A., Peterson, L. E., & Musser, J. M. (2013) · Archives of Pathology and Laboratory Medicine · doi:10.5858/arpa.2012-0651-oa · Cited by 388
Montassier, E., Batard, E., Gastinne, T., Potel, G., & Cochetière, M. F. (2013) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-013-1819-7 · Cited by 304
Christner, M., Rohde, H., Wolters, M., Sobottka, I., Wegscheider, K., & Aepfelbacher, M. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.01831-09 · Cited by 303
Therapeutic Strategies for Emerging Multidrug-Resistant Pseudomonas aeruginosa
Kunz Coyne, A. J., El Ghali, A., Holger, D., Rebold, N., & Rybak, M. J. (2022) · Infectious Diseases and Therapy · doi:10.1007/s40121-022-00591-2 · Cited by 275
Timing of antibiotic therapy in the ICU
Kollef, M. H., Shorr, A. F., Bassetti, M., Timsit, J.-F., Micek, S. T., Michelson, A. P., & Garnacho-Montero, J. (2021) · Critical Care · doi:10.1186/s13054-021-03787-z · Cited by 161
Banerjee, R., Komarow, L., Virk, A., Rajapakse, N., Schuetz, A. N., Dylla, B., Earley, M., Lok, J., Kohner, P., Ihde, S., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa528 · Cited by 138
Zasowski, E. J., Bassetti, M., Blasi, F., Goossens, H., Rello, J., Sotgiu, G., Tavoschi, L., Arber, M. R., McCool, R., Patterson, J. V., et al. (2020) · Chest · doi:10.1016/j.chest.2020.03.087 · Cited by 117
Kumar, A. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr090 · Cited by 92
Hung, Y.-P., Lee, C.-C., & Ko, W.-C. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.869822 · Cited by 29
Clinical Guideline for the Diagnosis and Treatment of Gastrointestinal Infections
The Korean Society of Infectious Diseases, Korean Society for Chemotherapy, & The Korean Society of Clinical Microbiology (2010) · Infection and Chemotherapy · doi:10.3947/ic.2010.42.6.323 · Cited by 18
Metadata
- Authors
- Lodise, T. P., Patel, N., Kwa, A., Graves, J., Furuno, J. P., Graffunder, E., Lomaestro, B., & McGregor, J. C.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2007-10
- Volume
- 51
- Issue
- 10
- Pages
- 3510-3515
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2098310975
- Cited by
- 318
- References
- 19
- FWCI
- 15.93
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.